Carlsmed Reports Strong Preliminary Q4 Revenue Growth of 61% and Full-Year 2025 Revenue Growth of 86%
CARL is trading near its 52-week low of $11.45 (11% above the low).
Summary
Carlsmed, Inc. announced robust preliminary and unaudited revenue for Q4 and full-year 2025, with significant growth driven by increased surgeon adoption of its aprevo® platform.
Key Events · Earnings and Guidance · CARL
-
Preliminary Q4 2025 Revenue
Reported approximately $15.2 million in revenue for the fourth quarter of 2025, marking a 61% increase compared to Q4 2024.
-
Preliminary Full Year 2025 Revenue
Announced approximately $50.5 million in revenue for the full year 2025, an 86% increase compared to full year 2024.
-
Surgeon User Growth
Added 101 new surgeon users in 2025, representing a 61% increase in the total surgeon user base over the prior year.
-
Product Expansion
Highlighted the recent launch of aprevo® cervical, a patient-specific cervical solution, with encouraging early surgeon feedback.
Analysis · CARL · Industrial Applications And Services
The strong preliminary revenue figures, showing 61% growth in Q4 2025 and 86% growth for the full year 2025, indicate significant commercial momentum for Carlsmed. The substantial increase in surgeon users for its aprevo® platform underscores successful product adoption and market penetration. While these results are unaudited and preliminary, the high growth rates suggest a positive trajectory for the company's AI-enabled personalized spine surgery solutions, potentially improving investor confidence ahead of full financial reporting.
At the time of this filing, CARL was trading at $12.69 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $342.3M. The 52-week trading range was $11.45 to $17.19. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.